Alex is a serial entrepreneur with over 30 years’ executive management and consulting experience in the medical device industry. In the past Alex served as CEO of Motorika, an Israel-U.S. manufacturer of medical robotics equipment. Earlier in his carrier he founded and served as CEO of Myriad Ultrasound Systems, an Israel-U.S developer and manufacturer of diagnostic ultrasound equipment for osteoporosis. Alex holds a BSc in Electrical and Computer Engineering from Ben Gurion University.

Nir has over 25 years’ experience in multidisciplinary product and system development, of which the last 15 he has served in management roles. In addition, he has led the creation, development, qualification and release of new products into the market, in collaboration with quality, regulatory and legal teams. Nir started his career as R&D engineer in the Israel Air Forces. He has an MBA as well as a B.Sc. in Electronics and Computer Science and has several patent applications and publications.

Rami joined keepMED with over 25 years of R&D leadership experience, both in med-tech and hi-tech. He has managed R&D and engineering teams at a number of Israeli companies, including eWaveMD and Medic4all, where he led product development from its earliest stages through regulatory approval and commercialization. Rami started his career in the elite 8200 intelligence unit of the Israel Defense Forces. He is the owner of several patents and holds a BSc in electrical engineering from Tel Aviv University.

Dr. Pierre-Charles Neuzeret has over 15 years’ experience in academic and industrial research organizations with previous managerial roles notably with global leaders in respiratory care medicine and digital healthcare. Before joining keepMED, he served as ResMed Science Center Manager for the EMEA to support ResMed sleep and respiratory care global strategy. At the beginning of his career, Pierre-Charles conducted research on the role of neurotransmitters involved in the control of pharyngeal patency and developed an experimental model for the screening of new pharmacological compounds to treat sleep apnea in partnership with Sanofi. Pierre-Charles holds a Phd from Claude Bernard University Lyon 1 (France), earned in the prestigious laboratory of Prof. Jouvet in Lyon.

Dr. Patrick Lévy, Professor of Physiology and respiratory physician, has been the head of the Hypoxia lab HP2 at Grenoble Alpes Univ. and Inserm (2003-2015), one of the most active research laboratories on sleep apnea worldwide. He has authored more than 350 international papers (H index WOS = 66 Nov’ 20) and has been a steering committee member of one of the major trials in sleep apnea, SERVE-HF. Prof. Levy is currently Section Editor for the Eur Resp J (IF: 12.34) and Associate Editor of J Sleep Res.

Anne Reiser served as the President of Emea-Apac-Japan at ResMed from 2014 until 2017. Previously she was President of Europe at ResMed since 2012, after running the French business since 2006. She has run her entire career in the medical device industry (Medtronic, Hollister, Zimmer, American Home Product and Mölnlycke), with leadership positions in France and Europe. She has been a board member during several years of the French Manufacturing Association and the French Notified Body (LNE). She holds a Master of Business degree from E. S.C. Clermont-Ferrand, a Bachelors in Law and an Executive Master from Sciences Po Paris. She has been based in France, Germany and Dubaï.

Dr. Valérie Calenda is a partner in Merieux Equity Partners, a global healthcare investment fund based in Lyon, France. In the past, Valérie led the project management of HCV and HPV programs at Transgene, an affiliate of Institut Mérieux, and contributed to their HPV therapeutic vaccine license agreement with Hoffmann La Roche. She was then in charge of Transgene’s  in-licensing and alliance management with Hoffmann La Roche before joining Mérieux Equity Partners. Valérie received her PhD in Pharmacology from the University of Marseille. She serves on the boards of three other companies – Proclara Biosciences (USA), Keranova (France), and PhysioAssist (France).

Eli Sorzon is the CEO and CFO of Xenia Venture Capital, an investment company publicly traded on the Tel Aviv Stock Exchange (TASE).
Xenia is engaged in investments in Life Science companies in Israel.
Eli has vast experience managing the entire scope of legal, financial, accounting and tax matters for several companies in various industries and stages. Before Joining Xenia, he served as Manager at the accounting firm Deloitte Brightman Almagor. Eli serves on the board of a number of technology companies.

Daniel Bertholet is the founder and managing partner of 4see Ventures, a boutique investment firm advising family offices and private investors in their venture capital investments. Previously, Daniel was Senior Investment Director at Endeavour Vision, where he invested in medtech and life science companies in Europe and the USA between 2003 and end-2017.  Daniel holds an MBA with honors from Science Po Paris.